Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial

Diabetologia

Volumn 58, Issue 7, 2015, Pages 1494-1502

  Soedamah Muthu, Sabita S ^a   Livingstone, Shona J ^b   Charlton Menys, Valentine ^c   Betteridge, D John ^d   Hitman, Graham A ^e   Neil, H Andrew W ^f   Bao, Weihang ^g   DeMicco, David A ^g   Preston, Gregory M ^g   Fuller, John H ^h   Stehouwer, Coen D A ⁱ   Schalkwijk, Casper G ^i,j   Durrington, Paul N ^c   Colhoun, Helen M ^b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d MIDDLESEX HOSPITAL   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g PFIZER INC   (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j MAASTRICHT UNIVERSITY   (Netherlands)

more..

Author keywords

Atorvastatin; C reactive protein; Cardiovascular disease; CARDS; LDL cholesterol; Statins; Type 2 diabetes

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DIABETIC ANGIOPATHIES; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ATORVASTATIN CALCIUM; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED;

EID: 84931562948     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3586-8     Document Type: Article

References (29)

1. Colhoun HM, Betteridge DJ, Durrington et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696
2. Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005–2016
3. Ridker PM, Rifai N, Lowenthal SP (2001) Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103:1191–1193
4. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S (2001) Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103:1933–1935
5. Nissen SE, Tuzcu EM, Schoenhagen P et al (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352:29–38
6. Ridker PM, Danielson E, Fonseca FA et al (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373:1175–1182
7. Ridker PM, Rifai N, Pfeffer MA et al (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98:839–844
8. Ridker PM, Cannon CP, Morrow D et al (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20–28
9. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E (2009) Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 29:424–430
10. Morrow DA, de Lemos JA, Sabatine MS et al (2006) Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 114:281–288
11. Sever PS, Poulter NR, Chang CL et al (2012) Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 33:486–494
12. Sever PS, Poulter NR, Chang CL et al (2013) Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J Am Coll Cardiol 62:717–729
13. Heart Protection Study Collaborative Group, Jonathan E, Derrick B et al (2011) C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 377:469–476
14. Blumenthal RS, Ndumele CE, Martin SS (2013) ASK NOT what CRP can do for you. J Am Coll Cardiol 62:730–731
15. Colhoun HM, Thomason MJ, Mackness MI et al (2002) Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 19:201–211
16. Thomason MJ, Colhoun HM, Livingstone SJ et al (2004) Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 21:901–905
17. WHO (1985) Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 727:1–113
18. Stone NJ, Robinson JG, Lichtenstein AH et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:2889–2934
19. Reiner Z, Catapano AL, de Backer G et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769–1818
20. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB (2004) C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 27:889–894
21. Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T (2006) High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 29:329–333
22. Bruno G, Fornengo P, Novelli G et al (2009) C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study. Diabetes 58:926–933
23. Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S (2012) Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies. Diabetes Care 35:396–403
24. Sattar N, Hingorani AD (2009) C-reactive protein and prognosis in diabetes: getting to the heart of the matter. Diabetes 58:798–799
25. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP (2002) C-reactive protein and myocardial infarction. J Clin Epidemiol 55:445–451
26. Jager A, van Hinsbergh VW, Kostense PJ et al (1999) von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 19:3071–3078
27. Emerging Risk Factors Collaboration group, Kaptoge S, Di Angelantonio E et al (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367:1310–1320
28. Kinlay S (2007) Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 49:2003–2009
29. Ridker PM (2013) Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc 124:174–190